Member Info for Moneymunch

Our aim was to interrogate SFN for efficacy against human coronaviruses.

We report here that SFN inhibits in vitro seasonal coronavirus HCoV-OC43 and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections of mammalian host cells and appears to have a synergistic interaction with remdesivir. In addition, SFN reduces viral load and pulmonary pathology in a mouse model of SARS-CoV-2 infection.

https://www.biorxiv.org/content/10.1101/2021.03.25.437060v1.full

Not peer reviewed yet, but published 25th March 2021 by John Hopkins University of Medicine, Baltimore, USA .....the next best thing and home of over 20 years of research into the therapeutic potential of Sulforaphane. Gl ;-)

"Hopkins scientists expand their 20-year mission to understand the disease-deterring benefits of a potent plant compound found in broccoli."

moneymunch

4 Apr '21 - 21:18 - 566 of 566  Edit

0  0 0

Ps a stunning validation of the risk reward for upside off the scale.:-)

Look no further...................................................................................SFX-01!!!!!!!!!!!!! ;-)

Courtesy of Bumpa, a great find and incredibly compelling and definitely tips the risk reward firmly in our favour. Gl :-)

Conclusion

We documented that SFN can inhibit the in vitro and in vivo replication of SARS-CoV-2 at pharmacologically and therapeutically achievable doses and can modulate the inflammatory response thereby decreasing the consequences of infection in the animal model when administered prior to infection. Given that SFN is orally bioavailable, commercially available, and has limited side-effects, our results suggest it could be a promising and easily scalable approach for the prevention and treatment of COVID-19 as well as other coronavirus infections.

https://www.biorxiv.org/content/10.1101/2021.03.25.437060v1.full

not ten, but should read "then almost everyday" !!!

Maybe sooner, dependent on when Prof Chalmers preliminary efficacy assessment on SFX-01's Covid/ARDS patient trial is reported and dependent on the outcome of that assessment. It was reported by RNS 17/2/21 that the Data Safety Monitoring Board's saftey assessment on the first 60 patients would be reported early Q2, yet results were published 11/3/21, which suggests Prof Chalmers efficacy assessment could come sooner rather than later. Positive data suggestig efficacy will be transformational for all invested.

As far as the selling is concerned, the vast majority of sells have been modest in size and ten almost every day we've had large late reported trades, many that have looked like buys, including Thursday's 499k late reported trade, which suggests that the MM's aren't in a hurry to raise the sp whilst there are pi's willing to sell their share under the 8p placing sp, and many of the late reported trades suggests that these cheap shares are being accumulated under the radar.

There's a raft of positive news that Huw could deliver from across the pipeline, but near term it would appear the market is awaiting news from prof Chalmers....everything firmly crossed that it will be good news , which would place Evgen in full investor focus and market appreciation and would be a complete game changer for all concerned. Excitement building in anticipation. Gla ;-)

Most of the sells below 8p have been modest in size which suggests weak and worried pi's have been happy to give up their shares cheaply, whilst they continue to accumulated on the cheap judging by the larger trades that appear during hours as well as the large trades that are reported after close....the MM's certainly won't be raising the sp anytime soon while the transfer of cheap shares into firm hands continues....I reckon it's just as plausible to suggest that they know positive data is coming from Prof Chalmers, as it is to suggest that the trial has failed, and the reason the MM's keep dropping the sp on small volume to encourage sellers...Gla holders....all will be revealed soon enough and who knows, but mayb Huw has got a massive golden egg for Easter to share with us..:-)

Maybe a knee jerk, chain reaction from those happy to sell sub 8p, obviously worried about negative data on SFX-01's Covid/ARDS trial.....everything firmly crossed that they will all regret not holding....news from Prof Chalmers this coming month imho. Gla :-)

Yes indeed RScorpio, the DSMB's safety assessment for the trial was expected to be published early Q2 according to Huw's update 17/2/21 yet news arrived 11/3/21 confirming no safety concerns, and so it's more than reasonable to expect Prof Chalmers preliminary efficacy assessment will arrive sooner rather than later. ....positive results will be a game changer, but it certainly appears that the markets expectations are zero, and so i'm sure that Huw will want the efficacy results released before any other development news from the rest of the pipeline, to ensure that any drop in sp on negative efficacy results will be short lived as other good news is delivered, but of course if Prof Chalmers surprises the market and delivers positive results, then those invested now will reap the rewards as the upside will likely be transformational, especially when further value will be added when Huw updates on other developments.....Fortune favours the Brave!!!!.....Excitement building. Gl ;-)

The 2m trade is priced as a buy and listed "Ordinary ", and so someone is soaking up all the shares that have been sold sub 8p by the looks of it....all bodes well. Gla :-)

Lol...snake oil or snake in the grass???...ha ha ha :-)

Maybe news this coming month on Prof Chalmers preliminary efficacy assessment , if SFX-01 works as well on humans, as SFN dosing appears to work on rabbits, positive data will be a game changer and transformational for all invested. Gla :-)

Sulforaphane significantly inhibits ARDS in rabbits and plays a protective role in ARDS through upregulating Nrf2.

https://www.researchgate.net/publication/324237365_Protective_mechanism_of_sulforaphane_in_Nrf2_and_anti-lung_injury_in_ARDS_rabbits

SFX-01 for breast cancer was life changing for some patients, tumour shrinkage and lives extended.......Gl ;-)

No concerns when the UK's leading and most powerful VC group, invests £1.75m in Evgen, along with Chelverton Assest Management's £1m and RAB Capiatl's £700k as well as AXA inreasing their holding by another £1m plus and Seneca by £750k, a supreme show of confidence in Evgen's prospects and potential going forward, fully funded until mid 2023 with multiple shots on multiple targets. Gla Holders....news on Prof Chalmers preliminary efficacy assessment from SFX-01's Covid/ARDS patient trials coming soon, positive data will be very well received. ;-)

March 2021

Event Voice: Your Questions Answered by Octopus Investments at Investment Select

Richard Power, Head of Quoted Smaller Companies at Octopus Investments

Can you give a brief overview of your strategy in terms of what you are trying to achieve for investors, your investment process and the make-up of the investment team?

The lead manager of the fund is Richard Power, who has been running the fund since its launch in 2007. Richard is directly assisted by Chris McVey and Dominic Weller in addition to the wider Quoted Companies Team at Octopus which consists of 8 investment professionals. The team manage a range of mandates focused on quoted smaller companies, including two AIM Venture Capital Trusts which ensures a good focus on, and understanding of, the smallest quoted companies. Collectively, the team manage £2.2bn.

We invest in small, relatively early-stage businesses. These micro cap companies tend to be sub-100 million. In general, we're looking for companies that can become relevant in their particular sector on a global scale and have the potential to grow to a multiple of the size they are at the point of investment.

Our philosophy is to become long-term co-owners in businesses that are very progressive and will become increasingly relevant in the world. We won't do what some other micro-cap funds might do, which is sell when companies get to a certain market cap. We'll continue to hold them until we think that they have reached a point where all of the upside is in the share price.

That means we've got a core portfolio of companies that are profitable and on a recognisable growth trajectory. We hope those businesses can double their profits in a three to five-year time horizon. A lot of our holdings have been in the portfolio for ten years and have gone up ten, 15 or 20-fold in that time.

https://www.investmentweek.co.uk/sponsored/4027908/event-voice-questions-answered-octopus-investments-investment-select

Lol SuperS, stick some of your BHR profit in here on Monday, fortune favours the brave....Gl :-)

Lol...it's crystal clear that you know the square root of f'all and the only gap is the one between your ears...ho ho ho.:-)

Near term are fortunes here are dependent on Prof Chalmers preliminary efficacy assessment on SFX-01 for Covid/ARDS, expected Q2, positive data should see significant upside and negative data could see a significant drop , although the sp should recover very quickly as other news from the rest of the pipeline is delivered.

Evgen confirmed 17/2/21 that the Data Safety Monitoring Board would assess safety on the first 60 patients and results would be published early Q2, yet results arrived earlier than stated on 11/3/21 confirming no safety concerns and Evgen confirmed at the same time that the DSBM would then assess the first 100 patients and Prof Chalmers would assess for efficacy, with results expected during Q2, and so it's highly possible that this assessment could already be in progress and results could arrive sooner rather than later, and so obviously i'm hoping Prof Chalmers efficacy results arrive before any other material news from the rest of the pipeline to cover all outcomes. Positive data will be a game changer and truly transformational for all concerned. Gla ;-)

Ps latest tweets from Prof Chalmers, that suggests long Covid could be inflammatory...here's hoping that SFX-01's anti-inlammatory potential and influence over the NRF2 pathway and oxidative stress etc has a part to play...interim analysis on efficacy could arrive this coming month.....positive data will be a game changer and totally Transformational for all concerned. Gla :-)

James D Chalmers’s Tweets

James D Chalmers

@ProfJDChalmers

·

42m

Other key takeaways - little relationship between severity of illness (ICU vs ward) and recovery. Everyone is at risk of Long-COVID - Clusters suggest a heterogeneous illness - Relationship between C-reactive protein and symptoms suggests long-covid could be inflammatory

1

4

Show this thread

James D Chalmers

@ProfJDChalmers

·

42m

Critical new data from the UK COVID-19 post-hospitalization consortium

@PHOSP_COVID

Shockingly low numbers of patients fully recovered at 5 months after discharge. Congratulations

@LeicesterBRC

@REvans_Breathe

@LouiseVwain

Proud to be a part of this https://medrxiv.org/content/10.1101/2021.03.22.21254057v1…

Quote Tweet

PHOSP-COVID study

@PHOSP_COVID

· 58m

7 in 10 hospitalised patients with #COVID19 not fully recovered, revealed by our study available on @medrxivpreprint today at: https://medrxiv.org/content/10.1101/2021.03.22.21254057v1… #LongCovid @uniofleicester @LeicesterBRC @uol3i @REvans_Breathe @LouiseVwain

On and UP!!! Gla :-)